CORDIS
EU research results

CORDIS

English EN

Identification and validation of novel pharmaceutical drug targets for cardiovascular disease

Objective

"Cardiovascular disease (CVD) is one of the major diseases in Europe and the Western world, killing over 2 million people per year in Europe alone and is the foremost cause of premature mortality and disability-adjusted life years, representing an annual economic cost of ∼€ 192 billion in direct and indirect healthcare expenses. The available therapies are insufficient to fulfill the need. The introduction of statins has reduced morbidity and mortality of atherosclerosis by 30%, however a large untreatable residual cardiovascularrisk remains even in cohorts of treated patients. Currently, many targets for CVD treatment have been selected based on mechanism of action and inference of functions in cellular models to clinical systems, and lack the rigorous clinical validation needed to maximize the chance for successful clinical drug development. Consequently, new drugs that modulate the activity of such targets fail later in clinical development by lack of efficacy or induction of safety liabilities due to off-target effects. To increase the success rate for clinical development of novel therapies in CVD, we will follow an innovative approach by using: 1. Independent and large-scale population studies from which novel targets with strong correlation to clinical phenotypes are deduced; 2. Translational disease-mimicking models (cellular and animal) to validate novel drug targets; 3. High quality human biobanks to confirm the molecular relevance of targets in diseased cardiovascular tissues; 4. A stringent pharmaceutical drug discovery process for prioritization of drugable targets. An important concept, in line with the changed pharmaceutical business model, is that these steps can best be executed by a functional network of clinical academic centers and specialized SMEs under the guidance of established and experienced drug discovery researchers from industry that brings together the right components and expertise to execute such a modular target discovery process."
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK TNO

Address

Anna Van Buerenplein 1
2595 Da Den Haag

Netherlands

Activity type

Research Organisations

EU Contribution

€ 939 353

Administrative Contact

Alain Van Gool (Prof.)

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany

EU Contribution

€ 700 083

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 598 000

ASTRAZENECA AB

Sweden

EU Contribution

€ 250 112

HJARTAVERND SES

Iceland

EU Contribution

€ 499 499

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 300 720

CARDIOGENX BV

Netherlands

EU Contribution

€ 701 024

POLYGENE AG

Switzerland

EU Contribution

€ 697 930

BIONEER A/S

Denmark

EU Contribution

€ 296 000

IMABIOTECH SAS

France

EU Contribution

€ 296 000

MORPHISTO EVOLUTIONSFORSCHUNG UND ANWENDUNG GMBH

Germany

EU Contribution

€ 295 000

UMEA UNIVERSITET

Sweden

EU Contribution

€ 200 000

MAARTEN DANIEL SOLLEWIJN GELPKE

United Kingdom

EU Contribution

€ 199 800

Project information

Grant agreement ID: 602936

Status

Closed project

  • Start date

    1 October 2013

  • End date

    30 September 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 980 425

  • EU contribution

    € 5 973 521

Coordinated by:

NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK TNO

Netherlands